Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

Dorthe Skovgaard; Morten Persson; Andreas Kjaer

doi:10.1016/j.cpet.2016.12.005

Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

Dorthe Skovgaard, Morten Persson, Andreas Kjaer^*

^*Corresponding author for this work

4 Citations (Scopus)

Abstract

Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using ⁶⁴Cu- and ⁶⁸Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

Original language	English
Journal	PET Clinics
Volume	12
Issue number	2
Pages (from-to)	243-255
Number of pages	13
ISSN	1556-8598
DOIs	https://doi.org/10.1016/j.cpet.2016.12.005
Publication status	Published - Apr 2017

Keywords

Molecular imaging
PET
Prostate cancer
Radionuclide imaging
Theranostics
uPAR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cpet.2016.12.005

Cite this

@article{a5f538e8caa44f519c95a3d2265f47b4,

title = "Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET",

abstract = "Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.",

keywords = "Molecular imaging, PET, Prostate cancer, Radionuclide imaging, Theranostics, uPAR",

author = "Dorthe Skovgaard and Morten Persson and Andreas Kjaer",

year = "2017",

month = apr,

doi = "10.1016/j.cpet.2016.12.005",

language = "English",

volume = "12",

pages = "243--255",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B.Saunders Co.",

number = "2",

}

TY - JOUR

T1 - Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

AU - Skovgaard, Dorthe

AU - Persson, Morten

AU - Kjaer, Andreas

PY - 2017/4

Y1 - 2017/4

N2 - Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

AB - Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

KW - Molecular imaging

KW - PET

KW - Prostate cancer

KW - Radionuclide imaging

KW - Theranostics

KW - uPAR

U2 - 10.1016/j.cpet.2016.12.005

DO - 10.1016/j.cpet.2016.12.005

M3 - Review

C2 - 28267457

AN - SCOPUS:85011088562

SN - 1556-8598

VL - 12

SP - 243

EP - 255

JO - P E T Clinics

JF - P E T Clinics

IS - 2

ER -

Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this